Protalix Biotherapeutics (NY: PLX )

1.080 +0.070 (+6.93%)
Official Closing Price Updated: 4:10 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,399
Open 1.070
Bid (Size) 1.020 (3)
Ask (Size) 1.080 (55)
Prev. Close 1.010
Today's Range 1.020 - 1.080
52wk Range 0.8214 - 1.900
Shares Outstanding 73,542,674
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-40.66%
-40.66%
1 Month
+5.88%
+5.88%
3 Month
+1.89%
+1.89%
6 Month
-16.92%
-16.92%
1 Year
-34.15%
-34.15%

More News

Read More
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Preview: Protalix BioTherapeutics
Via Benzinga
Earnings Scheduled For November 6, 2023
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 14, 2024
Via Benzinga
Pullix Gains Momentum As Gamestop Exits NFT Space
Via Talk Markets
Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Preview: Protalix BioTherapeutics's Earnings
Via Benzinga
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
Via Benzinga
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed
Via Benzinga
Protalix BioTherapeutics Well Placed to Advance in 2023
Via Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
Via Benzinga
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via News Direct
Exposures Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via TheNewswire.com
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.